Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on follicular lymphoma, susceptibility to, 1 is limited primarily due to its rarity and the complexity of its polygenic nature. Because this condition affects a relatively small population, systematic clinical studies have been challenging to conduct. Additionally, the absence of identified genes and clearly defined clinical features further complicates the understanding of FL1.
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphoproliferative disorders, particularly follicular lymphoma. Engaging with a genetic counselor may also be beneficial, especially given the polygenic nature of the condition. While no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support. Additionally, inquire about opportunities to participate in clinical trials or natural history studies to contribute to ongoing research.
There are currently 13 FDA-approved orphan drugs for the treatment of follicular lymphoma, including axicabtagene ciloleucel, copanlisib, and rituximab. Additionally, there are 21 orphan drugs designated for development, such as 177Lu-tetraxetan-tetulomab and various CAR T-cell therapies. For those interested in clinical trials, there is one active trial available. More information can be found at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=follicular%20lymphoma%2C%20susceptibility%20to%2C%201.
Actionable guidance for navigating care for follicular lymphoma, susceptibility to, 1
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphoproliferative disorders, particularly follicular lymphoma. Engaging with a genetic counselor may also be beneficial, especially given the polygenic nature of the condition. While no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support. Additionally, inquire about opportunities to participate in clinical trials or natural history studies to contribute to ongoing research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on follicular lymphoma, susceptibility to, 1 is limited primarily due to its rarity and the complexity of its polygenic nature. Because this condition affects a relatively small population, systematic clinical studies have been challenging to conduct. Additionally, the absence of identified genes and clearly defined clinical features further complicates the understanding of FL1.
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphoproliferative disorders, particularly follicular lymphoma. Engaging with a genetic counselor may also be beneficial, especially given the polygenic nature of the condition. While no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support. Additionally, inquire about opportunities to participate in clinical trials or natural history studies to contribute to ongoing research.
There are currently 13 FDA-approved orphan drugs for the treatment of follicular lymphoma, including axicabtagene ciloleucel, copanlisib, and rituximab. Additionally, there are 21 orphan drugs designated for development, such as 177Lu-tetraxetan-tetulomab and various CAR T-cell therapies. For those interested in clinical trials, there is one active trial available. More information can be found at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=follicular%20lymphoma%2C%20susceptibility%20to%2C%201.
Actionable guidance for navigating care for follicular lymphoma, susceptibility to, 1
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphoproliferative disorders, particularly follicular lymphoma. Engaging with a genetic counselor may also be beneficial, especially given the polygenic nature of the condition. While no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support. Additionally, inquire about opportunities to participate in clinical trials or natural history studies to contribute to ongoing research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on follicular lymphoma, susceptibility to, 1 is limited primarily due to its rarity and the complexity of its polygenic nature. Because this condition affects a relatively small population, systematic clinical studies have been challenging to conduct. Additionally, the absence of identified genes and clearly defined clinical features further complicates the understanding of FL1.
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphoproliferative disorders, particularly follicular lymphoma. Engaging with a genetic counselor may also be beneficial, especially given the polygenic nature of the condition. While no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support. Additionally, inquire about opportunities to participate in clinical trials or natural history studies to contribute to ongoing research.
There are currently 13 FDA-approved orphan drugs for the treatment of follicular lymphoma, including axicabtagene ciloleucel, copanlisib, and rituximab. Additionally, there are 21 orphan drugs designated for development, such as 177Lu-tetraxetan-tetulomab and various CAR T-cell therapies. For those interested in clinical trials, there is one active trial available. More information can be found at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=follicular%20lymphoma%2C%20susceptibility%20to%2C%201.
Actionable guidance for navigating care for follicular lymphoma, susceptibility to, 1
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in lymphoproliferative disorders, particularly follicular lymphoma. Engaging with a genetic counselor may also be beneficial, especially given the polygenic nature of the condition. While no specific patient organizations are identified, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide support. Additionally, inquire about opportunities to participate in clinical trials or natural history studies to contribute to ongoing research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.